EX-10.39
from 10-K
1 page
Vertex Pharmaceuticals Incorporated Annual Non-Employee Board Compensation Annual Retainer $100,000 Committee Chair Compensation Audit & Finance Committee Chair $30,000 Annual Retainer Management Development & Compensation Committee Chair $25,000 Annual Retainer Corporate Governance & Nominating Committee Chair $25,000 Annual Retainer Science & Technology Committee Chair $25,000 Annual Retainer Committee Membership Fee (Non-Chairs) Audit & Finance Committee Member $15,000 Annual Retainer Management Development & Compensation Committee Member $12,500 Annual Retainer Corporate Governance & Nominating Committee Member $10,000 Annual Retainer Science & Technology Committee Member $10,000 Annual Retainer Lead Independent Director Compensation $40,000 Annual Retainer Annual Equity Grants Annually on May 1, $400,000 in Value-Based Awards, Comprised at the Director's Election of Restricted Stock Units and/or Options •options Are Fully Vested Upon Grant •restricted Stock Units Cliff Vest on the 1 Year Anniversary of the Grant Date Initial Equity Grants on Date Director Joins the Board of Directors, a $400,000 Restricted Stock Unit Award That Vests on the First Anniversary of the Grant Date. Each of Our Non-Employee Directors Is Eligible to Defer the Cash and Restricted Stock Portion of His/Her Compensation Set Forth Above and Elect to Receive Deferred Stock Units That Convert to Common Stock in Specified Circumstances
12/34/56
EX-10.4
from 10-Q
15 pages
Certain Confidential Information Contained in This Document, Marked by [***], Has Been Omitted Because It Is Not Material and Would Likely Cause Competitive Harm to Vertex Pharmaceuticals Incorporated if Publicly Disclosed. Amendment No. 7 Research, Development and Commercialization Agreement, Dated May 24, 2004 by and Between Vertex Pharmaceuticals Incorporated and Cystic Fibrosis Foundation Therapeutics Incorporated
12/34/56
EX-10.3
from 10-Q
27 pages
Certain Confidential Information Contained in This Document, Marked by [***], Has Been Omitted Because It Is Not Material and Would Likely Cause Competitive Harm to Vertex Pharmaceuticals Incorporated if Publicly Disclosed. Amendment No. 5 to Research, Development and Commercialization Agreement, Dated May 24, 2004, by and Between Vertex Pharmaceuticals Incorporated and Cystic Fibrosis Foundation Therapeutics Incorporated
12/34/56
EX-10.41
from 10-K
1 page
Vertex Pharmaceuticals Incorporated Annual Non-Employee Board Compensation Annual Retainer $100,000 Committee Chair Compensation Audit & Finance Committee Chair $30,000 Annual Retainer Management Development & Compensation Committee Chair $25,000 Annual Retainer Corporate Governance & Nominating Committee Chair $20,000 Annual Retainer Science & Technology Committee Chair $20,000 Annual Retainer Committee Membership Fee (Non-Chairs) Audit & Finance Committee Member $15,000 Annual Retainer Management Development & Compensation Committee Member $12,500 Annual Retainer Corporate Governance & Nominating Committee Member $10,000 Annual Retainer Science & Technology Committee Member $10,000 Annual Retainer Lead Independent Director Compensation $40,000 Annual Retainer Annual Equity Grants Annually on May 1, $400,000 in Value-Based Awards, Comprised at the Director's Election of Restricted Stock Units and/or Options •options Are Fully Vested Upon Grant •restricted Stock Units Cliff Vest on the 1 Year Anniversary of the Grant Date Initial Equity Grants on Date Director Joins the Board of Directors, a $400,000 Restricted Stock Unit Award That Vests on the First Anniversary of the Grant Date. Each of Our Non-Employee Directors Is Eligible to Defer the Cash and Restricted Stock Portion of His/Her Compensation Set Forth Above and Elect to Receive Deferred Stock Units That Convert to Common Stock in Specified Circumstances
12/34/56
